Latest News

MMS Poised for an Innovative Future with Best Clinical Research Organization Award and Two Key Executive Appointments

CANTON, Mich. (July 21, 2021) – MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced the growth of its leadership team with the appointment of Kelly J. Hill to Executive Vice President (EVP) of Global Business Operations and Strategy and Michelle Gayari to Executive Vice President of Global Operational Excellence and Innovation. This comes as the company was awarded Best Data-Focused Biotech CRO in the International Life Sciences Awards. 

Hill and Gayari are long-time members of the executive leadership team at MMS, which has remained steadfast and unchanged for the past decade. Both EVPs are Pfizer alumni and, along with Chief Scientific Officer and Founder Dr. Uma Sharma, who began growing MMS into a global powerhouse after Pfizer closed its Ann Arbor doors in 2007.  

“We are grateful for Kelly and Michelle’s contributions to MMS, and their sense of urgency and leadership has allowed us to considerably expand our teams and company globally,” said Prasad M. Koppolu, Chief Operating Officer, MMS.  

Organic growth  

MMS has maintained strong, organic growth since its inception, and these most recent promotions reflect that. Hill and Gayari have been instrumental in leading company advancements, including expanding services, acquiring new clients, and implementing the USD1M award for COVID-19 vaccine development that MMS announced last year.  

Michelle Gayari MMS Holdings clinical research organization contract research organisation best CRO top CRO USA global biometrics data services clinical programming statistics data science covid-19 coronavirus

Michelle Gayari

In recent weeks, MMS surpassed a total of 800 colleagues across North America, Asia, Europe, and South Africa. 

“I’m grateful for this opportunity to continue building the MMS brand and bringing added value to Sponsor partners through strong teamwork and best-in-class tech-enabled services,” said Hill. 

Technology-focused future 

“The colleagues of MMS are proven innovators, and I am grateful to be a part of developing our diverse technology platforms to bring solutions to the industry and our clients,” said Gayari. “There is much more to come, and I’m excited to share these innovations with the industry.” 

This year, MMS will conduct its second annual Global Champions of Change Competition (G3C) in an effort to bring forth innovations from every level of the organization. The company currently has eight new innovations underway from the inaugural event, in addition to innovations in data science, medical writing, clinical trial transparency, and pharmacovigilance that are already in use by global sponsors.  

Learn more about our leadership and expertise at https://www.mmsholdings.com/executive-leadership/ 

ABOUT MMS 

MMS Holdings (MMS) is an innovative, data-focused CRO that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating, and the company has been recognized as a leading CRO in Global Health & Pharma’s international awards programs for the last three consecutive years.

For more information, visit www.mmsholdings.com or follow MMS on LinkedIn.

Suggested For You

news

October 15th, 2024

MMS Recognized with EcoVadis Bronze Medal for Leadership in ESG Sustainability Efforts as a Leading Clinical Research Organization (CRO)

news

July 17th, 2024

Industry Veteran Ben Dudley Joins MMS as Chief Commercial Officer (CCO) to Drive Continued Growth for the Data-focused Clinical Research Organization

news

April 4th, 2024

MMS Hires Pharmaceutical Industry Veteran James Zee for Global Biometrics Leadership in Europe Amid Strong Regional Growth

news

March 6th, 2024

MMS Holdings Inc – A Data-Centric CRO Powerhouse Reshaping Drug Development on a Global Scale

news

December 13th, 2023

MMS Supported Lykos Therapeutics: NDA Submitted to FDA for First Psychedelic-Assisted Therapy for PTSD

news

April 18th, 2023

MMS Named Great Place to Work in the UK as Growth in the Region Doubles

news

March 21st, 2023

MMS Scientific Advisory Board’s New Members Expand CRO’s Therapeutic Expertise

news

February 21st, 2023

MMS Partners with I-ACT to Advance Children’s Clinical Trials

news

February 7th, 2023

Award-Winning Data CRO Expands Executive Leadership to Support Company’s Next Stage of Growth

news

January 11th, 2023

MMS Named a Great Place to Work in India

news

November 21st, 2022

MMS Named Michigan Top Workplace For The Second Consecutive Year

news

August 16th, 2022

Together Trial with EDC Database Designed by MMS Wins Trial of the Year